Anupam Rasayan India Limited — Q4 FY26
Anupam Rasayan reported a strong FY26 with consolidated revenue of ₹2,384 crore (+65% YoY) and EBITDA of ₹543 crore (+32% YoY), driven by robust execution across agrochemicals,...
bullish
high
✓ Verified against BSE filing
Claim Ledger
Did management answer the analysts?
Every material analyst question, graded on whether management actually answered it — with the verbatim exchange and quantitative claims checked against filed numbers.
92%Questions answered0Evaded / deflected12Questions auditedMixedNumbers vs filing
Answered
High priority
Rationale for Bliss acquisition and whether current management will continue.
Asked by Sha, MK Global
Management clearly explained rationale and confirmed management continuity.
Read the exchange
Question
What was the rational behind the acquisition and would the current management of this JBS be continuing?
Vishal (CFO or similar, role not explicitly stated)
Yes the current management shall continue... The strategic rational... Anupam has been focusing on pharmaceutical industry... contribution from pharma has gone from practically 0% to 20%...
Answered
High priority
Pro forma revenue post consolidation and plans for merger/delisting of Bliss.
Asked by Tanya Chadri, Invest
Management gave specific pro forma numbers and clearly stated no merger/delisting plans.
Read the exchange
Question
What could the expected pro forma revenue contribution be post consolidation of all entities and whether there are any long-term plans around the merger or delisting of Bliss GBS Pharma.
Vishal
No... we would like to keep them independent... pro forma basis... Anupam should be around 1,676 crores, Standpack 711, Jhawk 722, Bliss 927... total over 4,000 crores revenue and EBITDA of around 834 crores.
Answered
High priority
Key synergies, timeline, funding structure, and EPS accretion from Bliss.
Asked by Tanya Chadri, Invest
Management provided specific timeline, funding details, and confirmed EPS accretion.
Read the exchange
Question
Could you also elaborate on the key synergies expected from the bliss acquisition the likely timeline for benefits to reflect and financial and what could the funding structure of the transaction be and is it expected to be EPS accretive going forward?
Vishal
Synergies will start playing out over near to medium term... 6 to 18 months... we will be raising debt/NCD of around 300 crores... balance as non-dilutive equity... yes it will be EPS accretive from day one.
Answered
High priority
Underlying revenue trajectory of base business excluding J-Hawk and business mix.
Asked by Tanya Chadri, Invest
Management gave growth rates and segment outlook.
Read the exchange
Question
Could you help us understand the underlying revenue trajectory of the base business excluding J-Hawk and how should we think about the evolving business mix going forward particularly with increasing contribution from the pharma and polymer segments.
Vishal
Standalone business has seen over 60 to 70% growth rate in annual revenues... growth of 20 to 30% over next 3 to 5 years on a core basis... pharma and polymer should deliver higher growth compared to agro.
Partial answer
Medium priority
Debt repayment schedule and interest cost post acquisitions.
Asked by Tanya Chadri, Invest
Management gave debt levels but did not provide interest cost or repayment schedule.
no interest cost guidance
Read the exchange
Question
How is the debt repayment schedule likely to shape up now post the recent acquisitions and what would the broad interest cost look like over the medium term?
Vishal
Balance sheet carries around 1,500 crores of debt on a consolidated gross level... net basis around 1,100... adding 300 crores, net debt around 1,400 to 1,500 crores... EBITDA over 650 crores... comfortable position.
Answered
High priority
Potential peak revenue from standalone gross block and maintenance capex.
Asked by Uncle Peru, Access Capital
Management gave specific revenue potential and maintenance capex range.
Read the exchange
Question
We have a gross block of around 2,500-2,600 crores on standalone side against current revenue of 1,700 crores. What is the potential peak revenue that we can do here with the current gross block?
Vishal
We should be looking at about 3,500 kind of a number from this block... maintenance capex of 50 to 75 crores over next 2-3 years.
Answered
High priority
Visibility on revenue growth from order book and synergies from J-Hawk/Bliss.
Asked by Uncle Peru, Access Capital
Management quantified order book and incremental revenue potential.
Read the exchange
Question
How much of this delta do we have a visibility on right now and how much of it is a function of the synergies coming from either J-Hawk or Bliss?
Vishal
Order book itself is around 14,000 crores... taking a 6-7 year average, we are talking about 1,700-1,800 crores of additional incremental revenue per year... synergies from J-Hawk and Bliss are on top of that.
Partial answer
Medium priority
Margin profile of pharma/polymer vs agro and working capital trajectory.
Asked by Uncle Peru, Access Capital
Management gave range but did not commit to specific margin improvement, citing ramp-up phase.
no specific margin guidancedeferred to ramp-up
Read the exchange
Question
Whether pharma polymer will be margin accretive versus agro and how do you see the working capital playing out?
Vishal
On a blended basis we should be able to look at those kind of numbers in the range that even this year's numbers represent... working capital should be in the range of 220-250 days... there will be upward bias to margins.
Answered
Medium priority
Tax rate guidance and common customers across Bliss/J-Hawk.
Asked by Uncle Peru, Access Capital
Management gave specific tax rate guidance and confirmed customer overlaps.
Read the exchange
Question
On the tax rate at least on the standalone side we have seen a sharp reduction. If you can guide what should we take that going ahead and are there any common customers across Bliss, J-Hawk, and standalone?
Vishal
We are envisaging a lower tax rate going forward... around about 25% as a tax rate... on J-Hawk yes there are common customers... on Bliss as well there are few customers where there will be overlap.
Answered
High priority
How to see Anupam over 3-5 years given acquisition spree and LOI revenue flow.
Asked by Meet Gara, Individual Investor
Management explained strategic vision and how acquisitions fit together.
Read the exchange
Question
How should one see Anupam over the next 3 to 5 years considering this multiverse acquisitions and how the LOI revenue will flow?
Vishal
The whole idea is supply chain or a platform to offer the larger value chain... Tanfac for backward integration, J-Hawk for performance materials, Bliss for pharma platform... synergies will take time but cross-leverage exists.
Answered
Medium priority
Why Bliss promoters sold and why they chose Anupam.
Asked by Meet Gara, Individual Investor
Management provided clear reasons for sale and selection of Anupam.
Read the exchange
Question
Why did the bliss promoters sell the company and why did they choose Anupam as a buyer?
Vishal
Succession planning... selling promoter is a senior citizen with two daughters... they believe in our vision, ethics, and what we did with Tanfac... they had other competing offers but honored commitment to us.
Answered
Medium priority
Structure of transaction and whether previous promoters also sold stake.
Asked by Drew Paj, Growth Sphere Ventures
Management explained the stake sale structure and rationale.
Read the exchange
Question
Was the structure in such a way that even the previous promoters like the Astas who reclassified from promoter group to public group also had to sell their stake?
Vishal
Any strategic acquirer would want as large a shareholding as possible... Mr. Asher also offered to sell along... they would love to keep about 5% shareholding because they believe in this growth.
Quantitative claims vs filed numbers
| Claim | Management said | Filing | Verdict |
|---|---|---|---|
| Standalone revenue growth 60-70% this year | 65% | 65% | Matches filing |
| Pro forma EBITDA over 650 crores on allocation basis | ₹650 cr | ₹543 cr | Overstated vs filing |
Filed figures sourced from Screener.in. Claims within a small tolerance of the filing are marked “matches filing”.